The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Fulvestrant Mylan 250 mg solution for injection in pre-filled syringe

Mylan Pharmaceuticals LimitedEU/1/17/1253/001-002

Main Information

Trade NameFulvestrant Mylan 250 mg solution for injection in pre-filled syringe
Active SubstancesFulvestrant
Dosage FormSolution for injection in pre-filled syringe
Licence HolderMylan Pharmaceuticals Limited
Licence NumberEU/1/17/1253/001-002

Group Information

ATC CodeL02BA Anti-estrogens
L02BA03 fulvestrant


License statusAuthorised
Licence Issued08/01/2018
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable List CodeIC0129-130-063
Interchangeable List DocumentPDF of Interchangeable List
« Back